Warsaw

• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended recruitment
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended recruitment
  2023-508256-19-00 9 2024-07-15 Unresectable Metastatic Non-small Cell Lung Cancer
• A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended recruitment
  2023-505608-43-00 4 2024-07-04 Moderate to Severe Hidradenitis Suppurativa
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509047-26-00 1 2024-06-13 Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse … Ended recruitment
  2023-508426-10-00 3 2024-06-03 Relapsed/Refractory Multiple Myeloma
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV … Ended recruitment
  2023-507456-69-00 4 2024-04-25 Atopic Dermatitis
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended recruitment
  2023-505782-86-00 5 2024-04-23 Vitiligo
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended recruitment
  2023-506011-18-00 5 2024-04-17 Vitiligo
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi … Ended recruitment
  2023-506301-20-00 9 2024-04-15 Tuberous Sclerosis Complex (TSC)
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Showing 913–936 of 1,708 trials